13G Filing: Highbridge Capital Management and Adverum Biotechnologies Inc. (ADVM)

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please

specify the type of institution:_______________________________________

(a)       Amount
beneficially owned:

As of the date hereof, (i) 1992 MSF International
Ltd. may be deemed to beneficially own 2,500,000 shares of Common Stock (including 200,000 shares of Common Stock issuable upon
exercise of call options) and (ii) Highbridge Capital Management, LLC, as the trading manager of 1992 MSF International Ltd., may
be deemed to be the beneficial owner of the 2,500,000 shares of Common Stock (including 200,000 shares of Common Stock issuable
upon exercise of call options) held by 1992 MSF International Ltd.

(b)       Percent
of class:

The percentages used herein and in the rest
of this Schedule 13G are calculated based upon 45,041,468 shares of Common Stock outstanding, as reported in the Company’s Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2017 filed with the Securities and Exchange Commission on November
8, 2017. Therefore, as of the date hereof, (i) 1992 MSF International Ltd. may be deemed to beneficially own approximately 5.55%
of the outstanding shares of Common Stock and (ii) Highbridge Capital Management, LLC may be deemed to beneficially own approximately
5.55% of the outstanding shares of Common Stock.

The foregoing should not be construed in and of itself as an admission
by any Reporting Person as to beneficial ownership of the shares of Common Stock held by 1992 MSF International Ltd.